TY - JOUR
T1 - Development of metaverse for intelligent healthcare
AU - Wang, Ge
AU - Badal, Andreu
AU - Jia, Xun
AU - Maltz, Jonathan S.
AU - Mueller, Klaus
AU - Myers, Kyle J.
AU - Niu, Chuang
AU - Vannier, Michael
AU - Yan, Pingkun
AU - Yu, Zhou
AU - Zeng, Rongping
N1 - Funding Information:
The adoption of MeTAI will require investment in software, hardware and infrastructure. One question is how MeTAI development will be funded. It is envisioned that the development and adoption of MeTAI will proceed in phases, each of which could be financed differently. First, in the exploratory phase, many technologies to enable MeTAI will need to be developed by companies and universities. At this phase, funding would mainly come as grants from government and industry. Once the feasibility is established, MeTAI enters an early adoption phase, where applications of MeTAI that offer incremental improvements with evident benefits could be adopted to enable cost savings. Due to its immediate value and potential financial savings, established companies and venture capitalists will have strong incentives to fund MeTAI development. In the next phase, more MeTAI technologies would be adopted to have high potential payoff, but possibly with risks. Such efforts are likely to be funded through venture capital. Technology innovators and early adopters will develop, test and demonstrate benefits to justify and attract investment. The assessment methods developed for other situations can be adapted to determine the value of MeTAI. ,
Funding Information:
This work was supported in part by NIH grants R01CA237267, R01HL151561, R01CA227289, R37CA214639, R01CA237269, R01CA233888, R01EB026646 and R01EB032716. We acknowledge discussions on data sharing with S. Zuehlsdorff at Siemens Medical Solutions USA. Figure 1 originally designed by the authors was artistically rendered by M. Esposito (https://www.markesposito.me). The mention of commercial products, their sources or use in connection with materials reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/11
Y1 - 2022/11
N2 - The metaverse integrates physical and virtual realities, enabling humans and their avatars to interact in an environment supported by technologies such as high-speed internet, virtual reality, augmented reality, mixed and extended reality, blockchain, digital twins and artificial intelligence (AI), all enriched by effectively unlimited data. The metaverse recently emerged as social media and entertainment platforms, but extension to healthcare could have a profound impact on clinical practice and human health. As a group of academic, industrial, clinical and regulatory researchers, we identify unique opportunities for metaverse approaches in the healthcare domain. A metaverse of ‘medical technology and AI’ (MeTAI) can facilitate the development, prototyping, evaluation, regulation, translation and refinement of AI-based medical practice, especially medical imaging-guided diagnosis and therapy. Here, we present metaverse use cases, including virtual comparative scanning, raw data sharing, augmented regulatory science and metaversed medical intervention. We discuss relevant issues on the ecosystem of the MeTAI metaverse including privacy, security and disparity. We also identify specific action items for coordinated efforts to build the MeTAI metaverse for improved healthcare quality, accessibility, cost-effectiveness and patient satisfaction.
AB - The metaverse integrates physical and virtual realities, enabling humans and their avatars to interact in an environment supported by technologies such as high-speed internet, virtual reality, augmented reality, mixed and extended reality, blockchain, digital twins and artificial intelligence (AI), all enriched by effectively unlimited data. The metaverse recently emerged as social media and entertainment platforms, but extension to healthcare could have a profound impact on clinical practice and human health. As a group of academic, industrial, clinical and regulatory researchers, we identify unique opportunities for metaverse approaches in the healthcare domain. A metaverse of ‘medical technology and AI’ (MeTAI) can facilitate the development, prototyping, evaluation, regulation, translation and refinement of AI-based medical practice, especially medical imaging-guided diagnosis and therapy. Here, we present metaverse use cases, including virtual comparative scanning, raw data sharing, augmented regulatory science and metaversed medical intervention. We discuss relevant issues on the ecosystem of the MeTAI metaverse including privacy, security and disparity. We also identify specific action items for coordinated efforts to build the MeTAI metaverse for improved healthcare quality, accessibility, cost-effectiveness and patient satisfaction.
UR - http://www.scopus.com/inward/record.url?scp=85141902783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141902783&partnerID=8YFLogxK
U2 - 10.1038/s42256-022-00549-6
DO - 10.1038/s42256-022-00549-6
M3 - Article
C2 - 36935774
AN - SCOPUS:85141902783
SN - 2522-5839
VL - 4
SP - 922
EP - 929
JO - Nature Machine Intelligence
JF - Nature Machine Intelligence
IS - 11
ER -